Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Opioid substitution treatment increases chances that people who inject drugs will have good adherence to HIV therapy

Opioid substitution treatment (OST) increases the chances of people who inject drugs achieving good adherence to highly active antiretroviral therapy (HAART) by 68%, Canadian investigators report in

Published
09 April 2015
By
Michael Carter
Limited Number of Mutations Responsible for Drug-Resistant HIV

"What we are showing is that the rates of transmitted drug-resistant HIV in the low- and middle-income countries most affected by HIV have increased modestly. The rate of increase in sub-Saharan Africa has been low, and an increase has not been detected in south Asia and Southeast Asia. That's good news," said Robert Shafer, M.D., professor of medicine at Stanford and principal investigator on the study.

Published
08 April 2015
From
Genetic Engineering & Biotechnology News
CUREiculum

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research, organizing into a systematic format for ongoing or issue-specific learning. The CUREiculum was developed in a multi-collaboratory process by leading scientists, community educators and various advocacy organizations who recognized the need for increasing literacy in this exciting arena. The tools are designed for community educators, funders, media and other stakeholders. Fifteen key areas of HIV cure research have been developed into free standing modules.

Published
08 April 2015
From
AVAC
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

Published
08 April 2015
From
Gilead press release
Kids Who Start HIV Treatment With Low CD4s Largely Regain Them

HIV-positive children who have low CD4 counts when starting treatment by and large experience a rebound to normal levels of those immune cells. After two years on HIV meds, 92 percent of the children achieved a CD4 count of 500 or above. Just nine children (1 percent) experienced an AIDS-defining illness during treatment. Children starting with fewer than 200 CD4 cells/mm3 took 1.29 years to reach a CD4 count over 500 cells/mm3.

Published
07 April 2015
From
AIDSMeds
Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir

People taking HIV treatment based on ritonavir-boosted atazanavir and darunavir have comparable long-term increases in lipid levels, investigators from the United States report in the online edition of

Published
06 April 2015
By
Michael Carter
Chinese study sheds light on how well treatment may work as prevention in the real world

A study from the Henan province of China published recently shows that antiretroviral therapy (ART) may not be as effective at suppressing HIV and preventing onward transmission

Published
01 April 2015
By
Gus Cairns
Predictors of HIV-related peripheral neuropathy in the modern era

Researchers at major clinical centres in the U.S. have collaborated to study potential causes of peripheral neuropathy (PN) among HIV-positive people in the modern era. They recruited about 500 people who were free from PN and monitored them for an average of two years, performing extensive assessments. Taking into account many issues, statistical analysis found that there were several factors associated with an increased risk for PN.

Published
01 April 2015
From
CATIE
Most HIV-positive gay men in European survey are on HIV treatment, though fewer in the east

The large EMIS survey of gay men living in Europe has found that over 70% of respondents with HIV are taking antiretroviral therapy (ART). Of those who

Published
30 March 2015
By
Gus Cairns
More people in the UK are starting HIV treatment early, in order to reduce their risk of transmission

There is evidence of increasing interest in HIV treatment as prevention among people living with HIV in the UK, with the number of people starting treatment at

Published
25 March 2015
By
Roger Pebody

Filter by country